CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026
Rhea-AI Summary
CVRx (NASDAQ: CVRX) said it will release fourth quarter 2025 financial and operating results after market close on Thursday, February 12, 2026. The company will host a conference call to review results at 4:30 p.m. Eastern Time the same day and provide a live webcast on its investor relations site.
Telephone access is available for U.S. callers at 1-877-704-4453 and international callers at 1-201-389-0920; callers are asked to dial in about ten minutes early.
Positive
- None.
Negative
- None.
News Market Reaction – CVRX
On the day this news was published, CVRX declined 2.09%, reflecting a moderate negative market reaction. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $184M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CVRX fell 5.04% while peers were mixed: BSGM up 39.91%, ELMD up 2.76%, SGHT up 0.33%, STIM down 4.5%, TLSI down 4.81%, suggesting stock-specific dynamics rather than a uniform sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 22 | Clinical trial launch | Positive | +8.6% | Launch of large BENEFIT-HF Barostim trial in expanded heart failure population. |
| Jan 12 | Prelim earnings/guidance | Positive | -9.9% | Preliminary Q4 and FY25 revenue plus 2026 guidance and operational updates. |
| Jan 06 | Reimbursement update | Positive | +3.3% | Implementation of new Category I CPT codes for Barostim therapy in the U.S. |
| Dec 22 | Investor conference | Neutral | -2.6% | Planned presentation at the 44th Annual J.P. Morgan Healthcare Conference. |
| Nov 19 | Investor conference | Neutral | -1.1% | Participation in a fireside chat at the Piper Sandler healthcare conference. |
News-driven moves generally align with sentiment: trial and reimbursement updates saw positive reactions, while preliminary earnings and guidance drew a negative divergence.
Over the last few months, CVRx has reported multiple milestones. On Jan 22, 2026, initiation of the BENEFIT-HF trial in an expanded heart failure population saw a +8.61% move. Preliminary Q4 and FY25 results plus 2026 guidance on Jan 12, 2026 led to a -9.86% reaction. Reimbursement and conference updates in late 2025 and early 2026 produced smaller but generally aligned moves. Today’s earnings date announcement fits this pattern of scheduled, informational updates.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Nov 6, 2025 allows CVRx to offer up to $150,000,000 of various securities via future supplements, one of which is already used for an ATM program.
Market Pulse Summary
This announcement sets the timetable for Q4 2025 results and a conference call on February 12, 2026, following recent updates on BENEFIT-HF and reimbursement. Historically, CVRX has shown positive reactions to clinical and coding milestones but a negative move around preliminary earnings and guidance. The existing $150,000,000 Form S-3 shelf and at-the-market program from January 2026 remain relevant context when interpreting future financing and capital structure decisions.
Key Terms
neuromodulation medical
AI-generated analysis. Not financial advice.
MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2025 financial and operating results after market close on Thursday, Feb. 12, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.
A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1- 877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
FAQ
When will CVRx (NASDAQ: CVRX) release Q4 2025 results and hold the conference call?
How can investors listen to the CVRx (CVRX) Q4 2025 earnings call on February 12, 2026?
What time is the CVRx (CVRX) conference call scheduled for the Q4 2025 results?
Where will CVRx (CVRX) host the webcast for its February 12, 2026 results announcement?
Should callers join early for the CVRx (CVRX) Feb. 12, 2026 earnings call and what are the recommended dial-in practices?
